Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: catherineiw who wrote (473)	6/1/1999 11:58:00 PM
From: Basildon Bond	Read Replies (1) \| Respond to of 518

NEWS (BSNS WIRE) Dr. LaSalle Leffall and Dr. Claude Tihon Accept Appointment Dr. LaSalle Leffall and Dr. Claude Tihon Accept Appointment as Members of Celsion's Board of Directors Business Editors and Health/Medical Writers COLUMBIA, Md.--(BW HealthWire)--June 1, 1999--Celsion Corp. (OTC BB:CELN) today announced that it appointed two individuals to its Board of Directors who are expected to bring a wealth of knowledge and experience to the Company. Dr. LaSalle D. Leffall is a surgeon, oncologist, medical educator, and leader in professional and civic organizations whose career includes serving as president of the American College of Surgeons and the American Cancer Society. He also serves as a director of Warner-Lambert Co. (NYSE:WLA), Mutual of America, Chevy Chase Bank, and the Charles A. Dana Foundation. A consultant to the National Cancer Institute, diplomat of the American Board of Surgery, and fellow of the American College of Surgeons and American College of Gastroenterology, Dr. Leffall was chairman of the Department of Surgery at Howard University College of Medicine. Currently, he holds the title of the Charles R. Drew Professor of Surgery at Howard. He is also a professorial lecturer in surgery at Georgetown University and has been visiting professor and guest lecturer at more than 200 medical institutions in the U.S. and other parts of the world. Dr. Leffall has authored or co-authored more than 130 articles and chapters. His professional life has been devoted to the study of cancer. Dr. Claude Tihon has over 20 years experience in medical devices, diagnostics, and pharmaceuticals. Dr. Tihon previously worked at Pfizer, Inc. (NYSE:PFE) as Vice President within the Pfizer Hospital Products Group. He performed in depth business and technology assessments, and contributed to business, strategic, and organizational developments of the American Medical Systems, a urological division of Pfizer, Inc. Dr. Tihon is president and CEO of ContiMed, a medical device company he founded in 1995 that developed urological products to manage women's stress incontinence and men's prostate obstruction. His past work also includes developing a human tumor cloning system, a human tumor cell-line based drug screening system, and several anti-cancer, and anti-viral compounds while at a division of Bristol-Myers Squibb Company (NYSE:BMY). At Miles Laboratories, he established a line of immunohistology products. During his career, Dr. Tihon directed the development of over 200 medical and diagnostic products. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's cancer treatment systems are being conducted by leading institutions such as the Massachusetts Institute of Technology, Massachusetts General Hospital, Montefiore Medical Center, and Duke University. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. --30--kf/bos* CONTACT: Celsion Corporation John Mon, 410/290-5390 www.celsion.com or OTC Financial Network Geoffrey Eiten, 888/399-7541 ext. 13 www.otcfn.com/celn KEYWORD: MARYLAND INDUSTRY KEYWORD: MEDICINE PHARMACEUTICAL MANAGEMENT CHANGES Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Basildon Bond